CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Trimesta

Synthetics Biologics

Synthetic Biologics Reports 2011 Year End Financial Results

The pharmaceutical startup Synthetic Biologics Inc. (NYSE Amex: SYN) reported a larger loss for the year ended Dec. 31, but also a host of promising operational highlights.

WWJ Newsradio 950–04/01/2012

Synthetics Biologics

Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS Drug

Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.

WWJ Newsradio 950–03/14/2012

adeona2

Adeona Starts Phase II Trials Of New MS Drug

Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had started a Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis in women.

WWJ Newsradio 950–01/19/2012

adeona2

Adeona Completes Enrollment In Phase II Trial Of MS Drug

Adeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.

WWJ Newsradio 950–09/19/2011

adeona

Adeona Multiple Sclerosis Clinical Trial Receives $1.6M Grant

Ann Arbor-based Adeona Pharmaceuticals Inc. announced Tuesday that after a scientific review, the ongoing clinical trial of its Trimesta oral estriol drug for multiple sclerosis has eeceived an additional $1,594,553 in grant funding from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke.

WWJ Newsradio 950–05/03/2011

adeona

Adeona’s Multiple Sclerosis Trial Receives $409,426 Grant

Ann Arbor-based Adeona Pharmaceuticals Inc. said Monday that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

03/28/2011

Follow

Get every new post delivered to your Inbox.

Join 1,875 other followers